← All trials
NCT00004992
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 1996
- Primary completion
- Apr 30, 2001
- Completion date
- Apr 30, 2001
- First posted
- Mar 20, 2000
- Last posted
- Mar 2, 2018
- Enrollment
- 3234
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Lead sponsor
- National Institutes of Health (NIH)Collaborator
- National Institutes of Health (NIH)Collaborator
- National Institute on Aging (NIA)Collaborator
- George Washington UniversityOverall official - principal investigator
- Office of Research on Women's Health (ORWH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.